Charles Schwab Investment Management Inc. Increases Holdings in Guardant Health, Inc. (NASDAQ:GH)

Charles Schwab Investment Management Inc. lifted its position in Guardant Health, Inc. (NASDAQ:GH) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,016,533 shares of the company’s stock after purchasing an additional 13,395 shares during the period. Charles Schwab Investment Management Inc. owned 0.82% of Guardant Health worth $31,055,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in Guardant Health during the fourth quarter worth $26,000. SBI Securities Co. Ltd. purchased a new stake in Guardant Health during the fourth quarter worth $43,000. Jones Financial Companies Lllp lifted its holdings in Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after buying an additional 817 shares during the period. Van ECK Associates Corp lifted its holdings in Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock worth $88,000 after buying an additional 929 shares during the period. Finally, KBC Group NV lifted its holdings in Guardant Health by 63.6% during the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after buying an additional 2,200 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $42.89 on Monday. The business’s 50-day moving average is $43.01 and its two-hundred day moving average is $32.94. The company has a market capitalization of $5.29 billion, a P/E ratio of -12.05 and a beta of 1.50. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Stifel Nicolaus upped their price target on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Canaccord Genuity Group upped their price target on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Raymond James reaffirmed an “outperform” rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Morgan Stanley upped their price target on Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Finally, Guggenheim reaffirmed a “buy” rating and set a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Twenty research analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health has a consensus rating of “Buy” and a consensus target price of $48.40.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.